MyLymphomaTeam

Polatuzumab vedotin (Polivy) can be given in several treatment scenarios. As a first-line treatment, it's now approved as part of the Pola-R-CHP combination for previously untreated advanced DLBCL. This combination includes polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone. For patients who Show Full Answer

Polatuzumab vedotin (Polivy) can be given in several treatment scenarios. As a first-line treatment, it's now approved as part of the Pola-R-CHP combination for previously untreated advanced DLBCL. This combination includes polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone. For patients who aren't eligible for a bone marrow transplant, polatuzumab vedotin may be given with or without bendamustine and/or rituximab as another treatment option. This flexibility in combination therapy allows doctors to tailor treatment based on individual patient needs and response.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Early vs. Advanced DLBCL: How Are They Treated Differently?

DLBCL Relapse Rate and Treatment Options